Open Clinical Trials

Breast

  • A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Antrhacycline, a Taxane, and Capecitabine
    Available at: Kerrville,  Metropolitan,  Northeast,  Stone Oak, 
  • A Randomized, Phase II Trial of Preoperative MM-121 with Paclitaxel in HER2-negative Breast Cancer
    Available at: Kerrville,  Metropolitan,  Northeast,  Stone Oak, 
  • An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab Drug Product (IMC-1121B) in Combination with Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane Therapy
    Available at: Metropolitan,  Northeast,  Stone Oak, 
  • A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination with Capecitabine for Adjuvant Treatment in Estrogen Receptor-Postive Early Stage Breast Cancer
    Available at: Kerrville,  Metropolitan,  Northeast,  Stone Oak, 
  • A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation and Radiation Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
    Available at: Kerrville,  Northeast,  Stone Oak, 
  • A Randomized, Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
    Available at: Northeast, 
  • A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate with Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer
    Available at: Kerrville,  Northeast,  Stone Oak, 
  • Randomized, Double-Blind, Placebo Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early Stage Breast Cancer at HIgh Risk of Recurrence
    Available at: Kerrville,  Metropolitan,  Northeast,  Stone Oak, 
  • A Randomized, Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Daily Everolimus in Combination with Trastuzumab and Vinorelbine, in Pretreated Women with HER2/neu Over-Expressing Locally Advanced or Metastatic Breast Cancer
    Available at: Kerrville,  Metropolitan,  Northeast,  Stone Oak, 

Breast Cancer and Bone Metastases

  • A Prospective, Randomized Double-Blind, Stratified, Placebo-Controlled, Multi-Center, Three-Arm Trial of the Continued Efficacy and Safety of Zometa (every 4 weeks vs. every 12 weeks vs. placebo) in Patients with Documented Bone Metastases from Breast Cancer
    Available at: Medical Center,  New Braunfels, 

Colorectal

  • A Randomized, Double Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil Plus Ramucirumab or Placebo in Patients with Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
    Available at: Kerrville,  Medical Center,  Metropolitan,  New Braunfels,  Northeast,  Stone Oak, 

Developmental Therapeutics

DVT

  • A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study for the Evaluation of Efficacy and Safey of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects with Symptomatic Deep-Vein Thrombosis and/or Pulmonary Embolism
    Available at: Medical Center,  New Braunfels, 
  • A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism
    Available at: Medical Center,  New Braunfels, 

Gynecology

  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of AMG 386 with Paclitaxel and Carboplatin as First-Line Treatment of Subjetcs with FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
    Available at: Kerrville,  Metropolitan,  Northeast,  Stone Oak, 

Head and Neck

  • A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who are Treated Without Surgery
    Available at: Northeast, 
  • Radiation Therapy Clinical Trial: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
    Available at: Northeast, 

Leukemia (CLL, CML)

  • Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase: The 5-Year Prospective Cohort Study
    Available at: Kerrville,  Northeast,  Stone Oak, 
  • A Phase III, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients with First Relapsed or Refractory Acute Myeloid Leukemia
    Available at: Medical Center, 

Lung

  • A Phase 2 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatinin Patients with Squamous Cell Carcinoma of the Lung (REO 021)
    Available at: Medical Center,  New Braunfels, 
  • An Open-label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-based Chemotherapy versus Platinum-based Chemotherapy Alone as First-line Treatment of Patients with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
    Available at: Kerrville,  Metropolitan,  Northeast,  Stone Oak, 
  • A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy
    Available at: Kerrville,  Medical Center,  New Braunfels,  Northeast,  Southeast,  Stone Oak, 
  • Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500 ig Once-Every-3-Weeks to a Hemoglobiin Ceiling of 12.0 g/dl in Anemic Subjects with Advanced Stage Non-Small Cell Lung Cancer Receiving Multi-Cycle Chemotherapy
    Available at: Kerrville,  Medical Center,  New Braunfels,  Northeast,  Stone Oak, 

Lymphoma

  • Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) Which Has Relapsed After Rituximab Therapy
    Available at: Medical Center,  New Braunfels, 
  • A Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma
    Available at: Kerrville,  Metropolitan,  Northeast,  Stone Oak, 
  • A Randomized, Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients With Agressive B-Cell Non-Hodgkins Lymphoma Who Have Relapsed After Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant
    Available at: Medical Center,  New Braunfels, 

Multiple Myeloma

Myelodysplasia

  • A Phase III Multicenter Randomized, Controlled Study to Assess the Efficacy and Safety of ONO1919/Na Administered as a 72 Hr. Continuous Intravenous Infusion Every Other Week in MDS patients with Excess Blasts Relapsing After, or Refractory to , or Intolerant to Azacitidine or Decitabine
    Available at: Medical Center,  New Braunfels, 
  • A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Deferasirox in Patients with Myelodysplastic Syndromes (low/int-1 Risk) and Transfusional Iron Overload
    Available at: Kerrville,  Medical Center,  New Braunfels,  Northeast,  Stone Oak, 

Pancreatic

  • A Phase I/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients with Pancreatic Cancer
    Available at: Metropolitan,  Northeast,  Stone Oak, 

Primary Myelofibrosis/Post-Essential Myelofibrosis/Post-Polycythemia Vera Myelofibrosis

  • An Open Label Assessment of Alternative Dosing Strategies of Ruxolitinib in Patients with Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis and Post-Essential Thrombocythemia-Myelofibrosis
    Available at: Medical Center,  New Braunfels, 
  • Open Label Assessment of Safety and Efficacy of Ruxolitinib in Patients with Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis and Post-Polycythemia Vera-Myelofibrosis Who Have Platelet Counts of 50 to 100
    Available at: Medical Center,  New Braunfels, 

Renal Cell

  • An Open-Label, Randomized, Multi-Center Phase III Study to Compare the Safety and Efficacy of TK1258 Versus Sorafenib in Patients with Metastastic Renal Cell Carcinoma After Failure of Anti-Angiogenic (VEGF-targeted and mTOR inhibitor therapies)
    Available at: Kerrville,  Northeast,  Stone Oak, 

Supportive Care

  • A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy (MED)
    Available at: Kerrville,  Medical Center,  Metropolitan,  New Braunfels,  Northeast,  Stone Oak, 
  • A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy
    Available at: Medical Center, 
  • Precision Therapeutics Registry Multicenter, Post Market Follow Up Study of ChemoFx Chemo Response Assay in Solid Tumors-ChemoFx Registry Study
    Available at: Medical Center,  New Braunfels,